Abstracts

Healthcare Resource Burden of Selected Nonseizure Symptoms Among Patients with Dravet Syndrome in the United States

Abstract number : 1.474
Submission category : 13. Health Services (Delivery of Care, Access to Care, Health Care Models)
Year : 2024
Submission ID : 1375
Source : www.aesnet.org
Presentation date : 12/7/2024 12:00:00 AM
Published date :

Authors :
Presenting Author: Mei Lu, MD, MS – Takeda Development Center Americas, Inc., Cambridge, MA, USA

Ahmed Noman, BS – Komodo Health, Inc.
Pam Kumparatana, MPH – Komodo Health, Inc.
Kenneth Taylor, PhD – Komodo Health, Inc.
Xinshuo Ma, MS – Komodo Health, Inc.
Queeny Ip, PhD, PharmD – Komodo Health, Inc.
Yuqin Wei, MS – Komodo Health, Inc.
Satish Rao, MD, MS, MD, MS – Takeda Development Center Americas, Inc., Cambridge, MA, USA

Rationale: Dravet syndrome (DS) is a rare neurodevelopmental disorder starting in childhood and causing seizures and nonseizure symptoms, which profoundly impact patients’ and caregivers’ lives. Few studies have quantified the economic burden associated with nonseizure symptoms in patients with DS. This study measured the healthcare resource utilization (HCRU) burden associated with nonseizure symptoms of interest (NSS; ie, communication issues, lack of alertness, disruptive behaviors).

Methods: Using Komodo’s Healthcare Map™ (October 2020-July 2023) closed claims data, this retrospective analysis included patients in the United States with ≥ 2 claims for DS. HCRU was compared between patients without NSS and patients diagnosed with NSS during a randomly selected 6-month continuously enrolled period on or after their diagnosis of DS. Adjusted logistic (for binary measures) and negative binomial (for count measures) regressions were used.

Results: Overall, 366 patients with and 674 without NSS were included in this analysis (Table 1). Of patients with NSS, 215 reported communication issues, 57 reported lack of alertness, 37 reported disruptive behavior, and 57 reported some combination. Median age was 9 and 14 years for patients with and without NSS, respectively. About half of patients (NSS/no NSS, %) were male (51/49) and most were insured by Medicaid (69/64). At the 6-month baseline, comorbidities tended to be more common among patients with NSS vs without NSS (%), including autism spectrum disorder (23/18), ADHD (11/7.0), and cognitive impairment (9.0/4.3). Other types of developmental delay were generally more common among patients with vs without NSS (72/59), including (NSS/no NSS, %) growth and nutrition (52/32), motor function (26/20), and sensory integration disorder (17/12). Seizure rates (%) were higher among patients with vs without NSS (any type: 93/84; generalized: 64/56; status epilepticus: 38/29), as were seizure-related injuries (11/7.9). During the 6-month follow-up, all-cause HCRU was significantly higher among patients with NSS vs those without (NSS/no NSS, mean visits; Table 2), including outpatient visits (41/22), home health and durable medical equipment (24/19), ER visits (1.3/0.5), ambulance services (0.7/0.3), inpatient stays (0.5/0.2), and ICU visits (0.2/0.1). Additionally, mean visits for safety monitoring (8.7/4.8), diagnostic tests (2.0/0.8), and supplemental treatment (10/2.0), including developmental delay therapy (10/1.8), were significantly higher among patients with vs without NSS. Pharmacy claims included (NSS/no NSS, %; all P < 0.05) maintenance antiseizure medications (ASMs; 96/91), rescue ASMs (63/49), and antipsychotics (7.4/5.6).
Health Services (Delivery of Care, Access to Care, Health Care Models)